OMS721
Phase 3Biologic
OMS721 is one of 45 biologic programs targeting Dense Deposit Disease. It is currently in Phase 3.
3
Indications
5
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
131 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPhase 3
Zemplar
AbbViePhase 3
Simulect
NovartisPhase 3
Ultomiris
AstraZenecaPhase 3
Acetadote
AArbor Pharmaceuticals, Inc.
Phase 3
Tekturna
Tibotec Pharmaceuticals, IrelandPhase 3
Aurlumyn
BBTG International Inc.
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Povetacicept
Vertex PharmaceuticalsPhase 3
Epoetin Beta
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Thrombotic Microangiopathy1 trial
Nephropathy1 trial
Safety and Efficacy1 trial
Dense Deposit Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OMS721. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- OOmeros Corporation